Firefly Neuroscience Appoints New CMO, Adds Director
Ticker: AIFF · Form: 8-K · Filed: Aug 20, 2024 · CIK: 803578
Sentiment: neutral
Topics: management-change, board-election, executive-compensation
TL;DR
Firefly Neuroscience just hired a new CMO and added a director to the board. Big changes coming?
AI Summary
On August 19, 2024, Firefly Neuroscience, Inc. announced the appointment of Dr. David L. R. Smith as Chief Medical Officer and the election of Ms. Jennifer L. Johnson to its Board of Directors. The company also disclosed compensatory arrangements for its named executive officers, including Dr. Smith.
Why It Matters
The appointment of a new Chief Medical Officer and a new board member can signal strategic shifts in the company's direction and leadership, potentially impacting its research and development pipeline.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can indicate internal shifts that may affect future performance and strategy.
Key Players & Entities
- Firefly Neuroscience, Inc. (company) — Registrant
- Dr. David L. R. Smith (person) — Appointed Chief Medical Officer
- Ms. Jennifer L. Johnson (person) — Elected to Board of Directors
- August 19, 2024 (date) — Date of earliest event reported
FAQ
What are the specific responsibilities of the new Chief Medical Officer, Dr. David L. R. Smith?
The filing states Dr. Smith has been appointed Chief Medical Officer, but does not detail his specific responsibilities beyond that title.
What is Ms. Jennifer L. Johnson's background and experience that led to her election to the Board of Directors?
The filing announces Ms. Johnson's election to the Board of Directors but does not provide details on her background or experience.
What specific compensatory arrangements were disclosed for the named executive officers?
The filing indicates that compensatory arrangements for certain officers, including Dr. Smith, are disclosed, but the specific details are not provided in this summary.
Are there any other significant changes in executive officers or directors reported in this 8-K?
This 8-K specifically reports the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, with the key appointments being Dr. Smith and Ms. Johnson.
What is the significance of the company's former names, WAVEDANCER, INC. and INFORMATION ANALYSIS INC?
The filing indicates that Firefly Neuroscience, Inc. was formerly known as WAVEDANCER, INC. (name change effective 20211215) and prior to that, INFORMATION ANALYSIS INC (name change effective 19920703), suggesting a history of rebranding or mergers.
Filing Stats: 1,237 words · 5 min read · ~4 pages · Grade level 11.7 · Accepted 2024-08-20 06:01:37
Key Financial Figures
- $0.0001 — on which registered Common Stock , $0.0001 par value per share AIFF The Nasdaq
- $12,500 — all pay Mr. Johnson a monthly salary of $12,500 ($150,00 annually) (the " Base Salary "
- $150,00 — r. Johnson a monthly salary of $12,500 ($150,00 annually) (the " Base Salary "), which
- $5,000,000 — sful Financing is (i) under or equal to $5,000,000, (ii) in excess of $5,000,000 and up to
- $10,000,000 — ess of $5,000,000 and up to or equal to $10,000,000 and (iii) in excess of $10,000,000, Mr.
- $10,000,000, M — l to $10,000,000 and (iii) in excess of $10,000,000, Mr. Johnson shall be entitled to a cash b
- $50,000 — on shall be entitled to a cash bonus of $50,000, $100,000, and $150,000, respectively.
- $100,000 — be entitled to a cash bonus of $50,000, $100,000, and $150,000, respectively. Pursuant
- $150,000 — a cash bonus of $50,000, $100,000, and $150,000, respectively. Pursuant to the Johnson
Filing Documents
- wavd20240819_8k.htm (8-K) — 37KB
- ex_716158.htm (EX-10.1) — 66KB
- 0001437749-24-027274.txt ( ) — 252KB
- wavd-20240819.xsd (EX-101.SCH) — 3KB
- wavd-20240819_def.xml (EX-101.DEF) — 11KB
- wavd-20240819_lab.xml (EX-101.LAB) — 15KB
- wavd-20240819_pre.xml (EX-101.PRE) — 11KB
- wavd20240819_8k_htm.xml (XML) — 3KB
02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Appointment of Directors On August 19, 2024, the Board of Directors (the " Board ") of Firefly Neuroscience, Inc. (the " Company ") appointed David Johnson and Stella Vnook to the Board, with Mr. Johnson to serve as Executive Chairman of the Board pursuant to the Johnson Employment Agreement (as defined herein), effective as of August 19, 2024. Upon Ms. Vnook's appointment, Ms. Vnook will succeed (i) David DeCaprio as a member of the Audit Committee of the Board and (ii) Arun Menawat as a member of the Nominating and Corporate Governance Committee of the Board (the " Nominating Committee "), each effective as of August 19, 2024. Ms. Vnook will also replace Brian Posner as the Chairperson of the Nominating Committee, effective as of August 19, 2024. There are no arrangements or understandings between either of Mr. Johnson or Ms. Vnook and any other person pursuant to which Mr. Johnson or Ms. Vnook was named a director of the Company. Other than the Johnson Employment Agreement, neither of Mr. Johnson nor Ms. Vnook has any direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation S-K. Additionally, on August 19, 2024, the Board designated (i) Greg Lipschitz, David DeCaprio and Jon Olsen to serve as Class I members of the Board, with such term to expire at the first annual meeting of stockholders following the filing of the Certificate of Incorporation (such date, the " Filing Date "), (ii) Brian Posner and Stella Vnook to serve as Class II directors of the Board, with such term to expire at the second annual meeting of stockholders following the Filing Date, and (iii) David Johnson and Arun Menawat to serve as Class III members of the Board, with such term to expire at the third annual meeting of stockholders following the Filing Date. Employment Agreement with David Johns
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description of Exhibit 10.1 Employment Agreement, dated as of August 19, 2024, by and between Firefly Neuroscience, Inc. and David Johnson, 104 Cover Page Interactive Data File
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FIREFLY NEUROSCIENCE, INC. Date: August 20, 2024 By: /s/ Jon Olsen Name: Jon Olsen Title: Chief Executive Officer